Lurbinectedin produced an overall response rate of 14.3% and a disease control rate of 57.1%.
High-dose treosulfan plus melphalan followed by autologous stem cell reinfusion did not improve event-free or overall survival.
Nearly 70% of patients had at least 1 potentially actionable therapeutic target.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of Li-Fraumeni syndrome.
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
In a pooled analysis of 6 studies, 44% of patients responded to combination irinotecan and temozolomide.
Cesarean was associated with increased risk of any cancer, hematopoietic cancers, and solid tumors.
Black individuals had the highest incidence of osteosarcoma, but the worst survival was seen in American Indian/Alaska Native individuals.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Kaposi sarcoma.
Systematic lymph node dissection did not provide a survival benefit over sentinel lymph node biopsy alone in patients with uterine carcinosarcoma.
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa.
Researchers sought to measure the risk of long-term neurocognitive outcomes in survivors of osteosarcoma and Ewing sarcoma.
The rate of hyperprogressive disease was 11%.
The approval of Fyarro was based on data from the phase 2 AMPECT study.
NBTXR3 plus radiotherapy did not negatively affect quality of life or long-term morbidity in locally advanced soft tissue sarcoma.
Researchers found that lack of radiosensitivity was associated with poor outcomes in patients with myxoid liposarcomas.
Neoadjuvant and adjuvant radiotherapy were associated with a reduced risk of local recurrence.
Most patients included in the retrospective analysis received ICI treatment as their first line of therapy (59%).
Stable disease was observed in 51.3% of patients.
Amputation was significantly more likely in patients with household incomes below $75,000 per year.